Welcome


NovAliX is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing.

With proprietary SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry, NovAliX offers comprehensive integrated services for small molecule drug discovery.

With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.

NovAliX Group, a team of 120 scientists, is located in state-of-the-art laboratory facilities in Strasbourg-Illkirch (France) and Heidelberg (Germany), and has a global footprint with clients around the world.


R&D
an image

For drug discovery, NovAliX offers target-driven solutions from hit finding to lead optimization by combining its chemistry and structural biology original expertise with outstanding biophysical technologies.

NovAliX further supports small molecules programs with process R&D experience, know-how and capabilities.

Technologies
 

NMR

an image

Native
MS

an image

Structural
Biology

an image

SPR

an image



  Return to top

Meet us
Meet our team in Berlin at the EFMC-ISMC meeting (booth 8) and also join us at the workshop organized by Novalix on biophysical techniques in drug discovery (04/09 at 12:15).

Novalix is exhibiting at Chemoutsourcing in Long Branch,NJ (10-13 september 2012).

Highlight
November 18, 2013

THE NOVALIX/KYOWA HAKKO KIRIN ALLIANCE WILL COMMENCE A FRAGMENT-BASED DRUG DISCOVERY PROJECT TARGETING AN IMPORTANT PROTEIN/PROTEIN INTERACTION
Read more...


January 14, 2013

NovAliX enters into fragment-based drug discovery alliance with KYOWA HAKKO KIRIN
Read more...


October 17, 2012

NovAliX Names Dr Luc Van Hijfte as CSO Drug Discovery.
Read more...


October 9, 2012

NovAliX and Servier Collaborate in Early Discovery Research Program.
Read more...


January 12, 2011

NovAliX SAS announced today that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.
Read more...


September 13, 2011

NovAliX to collaborate with Fondation Jérôme Lejeune on Down syndrome (trisomy 21).
Read more...


August 29, 2011

NovAliX and Galapagos collaborate in osteoarthritis discovery research program.
Read more...


March 30, 2011

Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies (www.novalix.com), announced today that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co., Ltd.
Read more...


Contact Information
an image
NovAliX
BioParc, bld Sebastien Brant,
67400 Illkirch
Email: info@novalix-pharma.com

Phone: +33 (0) 368 330 200
Fax: +33 (0) 368 330 201